Answers are grounded in this paper and cite their sources.
BMS-986141 is a novel potent highly selective antagonist of PAR (protease-activated receptor) type 4. PAR4 antagonism has been demonstrated to reduce thrombus formation in isolation and in combination with factor Xa inhibition in high shear conditions in healthy people. We sought to determine whether PAR4 antagonism had additive antithrombotic effects in patients with coronary artery disease who were receiving antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Nash et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: